Linnaeus Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2026-02-27.
Linnaeus Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on February 27, 2026. The filing reports $4.99M sold. Its industry group is Biotechnology. It names Patrick Mooney (Executive Officer, Director), James Demetriades (Director), Michael Poisel (Director) (SEC Form D/A, February 27, 2026).
Sell to companies like Linnaeus Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-02-27 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Linnaeus Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Linnaeus Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in New Jersey, filed within 90 days of this one, largest first.
Get an email when Linnaeus Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Linnaeus Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Linnaeus Therapeutics, Inc. →Get the full cited report on Linnaeus Therapeutics, Inc.
What the filing shows about Linnaeus Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Linnaeus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Linnaeus Therapeutics, Inc. →
Amended on 2026-04-02: the amount sold changed from $4,475,000 to $4,992,000; the number of investors changed from 19 to 26. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Linnaeus Therapeutics, Inc. See pricing
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $4.99M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Patrick Mooney is named as Executive Officer and Director on the Form D that Linnaeus Therapeutics, Inc. filed with the SEC on 27 February 2026, one of 6 people that filing names.
James Demetriades is named as Director on the Form D that Linnaeus Therapeutics, Inc. filed with the SEC on 27 February 2026, one of 6 people that filing names.
Michael Poisel is named as Director on the Form D that Linnaeus Therapeutics, Inc. filed with the SEC on 27 February 2026, one of 6 people that filing names.
Chris Arendt is named as Director on the Form D that Linnaeus Therapeutics, Inc. filed with the SEC on 27 February 2026, one of 6 people that filing names.
Todd Thomson is named as Director on the Form D that Linnaeus Therapeutics, Inc. filed with the SEC on 27 February 2026, one of 6 people that filing names.
John Lepping is named as Director on the Form D that Linnaeus Therapeutics, Inc. filed with the SEC on 27 February 2026, one of 6 people that filing names.
6 people named on the filing — 1 holding an executive role and 5 as directors only.
Named as of the 2026-02-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Linnaeus Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Linnaeus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Linnaeus Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Linnaeus Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Linnaeus Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Linnaeus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/linnaeus-therapeutics-inc-form-d-26000001